Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$13.18

0.06 (0.46%)

, RHHBY

Roche

$30.54

-0.29 (-0.94%)

04:51
10/07/16
10/07
04:51
10/07/16
04:51

Exelixis announces Genentech presentation of preliminary phase 1b trial results

Exelixis (EXEL) announced that its collaborator Genentech, a member of the Roche Group (RHHBY), will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma. The results will be the subject of a poster discussion presentation at the European Society of Medical Oncology 2016 Congress, which is being held October 7-11 in Copenhagen, Denmark. "Cobimetinib and vemurafenib is FDA-approved to treat specific forms of BRAF V600 mutation-positive unresectable or metastatic melanoma and has been associated with significant improvements in progression-free survival, overall survival and objective response rate as compared to vemurafenib alone," said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. "The preliminary results to be presented at the ESMO Congress suggest that adding atezolizumab to the combination regimen is associated both with a manageable safety profile and promising antitumor activity."

EXEL

Exelixis

$13.18

0.06 (0.46%)

RHHBY

Roche

$30.54

-0.29 (-0.94%)

  • 07

    Oct

  • 10

    Oct

  • 10

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

EXEL Exelixis
$13.18

0.06 (0.46%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.
RHHBY Roche
$30.54

-0.29 (-0.94%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

VDNRF

Vedanta Resources

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Downgrade
Vedanta Resources rating change  »

Vedanta Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$134.14

2.16 (1.64%)

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Options
Notable pre-earnings option play in Expedia »

Notable pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

10:40
04/25/17
04/25
10:40
04/25/17
10:40
General news
Treasury Option Action: a round of positioning »

Treasury Option Action: a…

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:39
04/25/17
04/25
10:39
04/25/17
10:39
Hot Stocks
JetBlue says fleet review 'going to take a little bit of time' »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

, SSNLF

Samsung

10:38
04/25/17
04/25
10:38
04/25/17
10:38
Periodicals
Samsung to give new MRAM memory details next month, Patently Apple says »

Following on a report…

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

SSNLF

Samsung

IBM

IBM

$161.45

0.7 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

AVXS

AveXis

$79.18

2.42 (3.15%)

10:37
04/25/17
04/25
10:37
04/25/17
10:37
Hot Stocks
AveXis says AVXS-101 appears to have favorable safety profile in Phase 1 trial »

AveXis presented results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TSLA

Tesla

$308.03

2.43 (0.80%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Periodicals
Union workers claim Tesla illegally intimidated them, BuzzFeed says »

The United Automobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

AEP

American Electric

$67.86

-0.11 (-0.16%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Hot Stocks
American Electric says to invest $17.3B in capital over next three years »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

10:35
04/25/17
04/25
10:35
04/25/17
10:35
General news
U.S. consumer confidence fell to a still-robust 120.3 »

U.S. consumer confidence…

FCX

Freeport McMoRan

$13.19

0.955 (7.81%)

10:34
04/25/17
04/25
10:34
04/25/17
10:34
Hot Stocks
Freeport McMoRan says near-term debt situation ins manageable »

At some point looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Hot Stocks
JetBlue says early A321NEOs have Pratt & Whitney GTF engines »

JetBlue says "We…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

UTX

United Technologies

$117.06

0.74 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

BIIB

Biogen

$276.86

3.92 (1.44%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Recommendations
Biogen analyst commentary  »

With Spinraza 'just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

UNXL

Uni-Pixel

$0.80

-0.01 (-1.23%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Options
Uni Pixel with higher call volume »

Uni Pixel with higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

10:30
04/25/17
04/25
10:30
04/25/17
10:30
General news
The 5.8% March U.S. new home sales surge »

The 5.8% March U.S. new…

EAT

Brinker

$43.93

-1.53 (-3.37%)

10:29
04/25/17
04/25
10:29
04/25/17
10:29
Hot Stocks
Brinker says 'comfortable' with guidance provided for FY17 »

Management said on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

JBLU

JetBlue

$21.75

0.22 (1.02%)

10:28
04/25/17
04/25
10:28
04/25/17
10:28
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on JetBlue, Embraer »

JetBlue says timing…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

QQQ

PowerShares QQQ Trust

$134.16

1.6 (1.21%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Technical Analysis
PowerShares QQQ Trust hits fresh 52-week highs »

The breakout that began…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

C

Citi

$60.29

0.85 (1.43%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Citi confirms receipt of CMA license in Saudi Arabia »

The Saudi Arabian Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

  • 25

    Jul

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
JetBlue aiming for CASM ex-fuel flat to up 1% for 2018-2020 »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BBRY

BlackBerry

$9.29

0.21 (2.31%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$81.41

-2.01 (-2.41%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Eli Lilly says hasn't contemplated scenario to not pursue baricitinib in RA »

On Eli Lilly's Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

10:25
04/25/17
04/25
10:25
04/25/17
10:25
General news
U.S. Richmond Fed manufacturing index dipped to 20 in April »

U.S. Richmond Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.